Harvard Bioscience Stock Net Income
| HBIO Stock | USD 2.24 0.03 1.32% |
Harvard Bioscience fundamentals help investors to digest information that contributes to Harvard Bioscience's financial success or failures. It also enables traders to predict the movement of Harvard Stock. The fundamental analysis module provides a way to measure Harvard Bioscience's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Harvard Bioscience stock.
| Last Reported | Projected for Next Year | ||
| Net Loss | -3.4 M | -3.6 M | |
| Net Loss | -8.6 M | -8.1 M | |
| Net Loss | -3.3 M | -3.4 M | |
| Net Loss | (0.08) | (0.08) | |
| Net Income Per E B T | 1.34 | 1.40 |
Harvard | Net Income |
Harvard Bioscience Company Net Income Analysis
Harvard Bioscience's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Harvard Bioscience Net Income | (3.42 M) |
Most of Harvard Bioscience's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Harvard Bioscience is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Harvard Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Harvard Bioscience is extremely important. It helps to project a fair market value of Harvard Stock properly, considering its historical fundamentals such as Net Income. Since Harvard Bioscience's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Harvard Bioscience's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Harvard Bioscience's interrelated accounts and indicators.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Harvard Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Harvard Bioscience reported net income of (3.42 Million). This is 101.0% lower than that of the Life Sciences Tools & Services sector and 103.43% lower than that of the Health Care industry. The net income for all United States stocks is 100.6% higher than that of the company.
Harvard Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Harvard Bioscience's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Harvard Bioscience could also be used in its relative valuation, which is a method of valuing Harvard Bioscience by comparing valuation metrics of similar companies.Harvard Bioscience is currently under evaluation in net income category among its peers.
Harvard Bioscience ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Harvard Bioscience's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Harvard Bioscience's managers, analysts, and investors.Environmental | Governance | Social |
Harvard Bioscience Institutional Holders
Institutional Holdings refers to the ownership stake in Harvard Bioscience that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Harvard Bioscience's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Harvard Bioscience's value.| Shares | Geode Capital Management, Llc | 2024-09-30 | 912.6 K | Meros Investment Management, Lp | 2024-09-30 | 833.6 K | Renaissance Technologies Corp | 2024-09-30 | 724.1 K | State Street Corp | 2024-06-30 | 709.6 K | Acuitas Investments, Llc | 2024-09-30 | 491.1 K | Northern Trust Corp | 2024-09-30 | 452 K | Acadian Asset Management Llc | 2024-06-30 | 423 K | Bard Associates Inc | 2024-09-30 | 312.4 K | Bank Of New York Mellon Corp | 2024-06-30 | 274.6 K | Blackrock Inc | 2024-06-30 | 2.8 M | Punch & Associates Inv Mgmt Inc | 2024-09-30 | 2.8 M |
Harvard Fundamentals
| Return On Equity | -0.2 | ||||
| Return On Asset | -0.0198 | ||||
| Profit Margin | (0.15) % | ||||
| Operating Margin | (0.08) % | ||||
| Current Valuation | 140.13 M | ||||
| Shares Outstanding | 43.62 M | ||||
| Shares Owned By Insiders | 7.77 % | ||||
| Shares Owned By Institutions | 73.88 % | ||||
| Number Of Shares Shorted | 398.85 K | ||||
| Price To Earning | (25.00) X | ||||
| Price To Book | 1.52 X | ||||
| Price To Sales | 1.00 X | ||||
| Revenue | 112.25 M | ||||
| Gross Profit | 62.29 M | ||||
| EBITDA | 9.49 M | ||||
| Net Income | (3.42 M) | ||||
| Cash And Equivalents | 4.26 M | ||||
| Cash Per Share | 0.10 X | ||||
| Total Debt | 42.77 M | ||||
| Debt To Equity | 0.73 % | ||||
| Current Ratio | 2.42 X | ||||
| Book Value Per Share | 1.50 X | ||||
| Cash Flow From Operations | 14.03 M | ||||
| Short Ratio | 3.22 X | ||||
| Earnings Per Share | (0.33) X | ||||
| Price To Earnings To Growth | 2.89 X | ||||
| Target Price | 6.25 | ||||
| Number Of Employees | 391 | ||||
| Beta | 1.31 | ||||
| Market Capitalization | 97.7 M | ||||
| Total Asset | 137.37 M | ||||
| Retained Earnings | (145.6 M) | ||||
| Working Capital | 22.5 M | ||||
| Current Asset | 50.55 M | ||||
| Current Liabilities | 19.32 M | ||||
| Net Asset | 137.37 M |
About Harvard Bioscience Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Harvard Bioscience's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Harvard Bioscience using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Harvard Bioscience based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
When determining whether Harvard Bioscience offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Harvard Bioscience's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Harvard Bioscience Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Harvard Bioscience Stock: Check out Harvard Bioscience Piotroski F Score and Harvard Bioscience Altman Z Score analysis. To learn how to invest in Harvard Stock, please use our How to Invest in Harvard Bioscience guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Harvard Bioscience. If investors know Harvard will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Harvard Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.80) | Earnings Share (0.33) | Revenue Per Share 2.258 | Quarterly Revenue Growth (0.13) | Return On Assets (0.02) |
The market value of Harvard Bioscience is measured differently than its book value, which is the value of Harvard that is recorded on the company's balance sheet. Investors also form their own opinion of Harvard Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Harvard Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Harvard Bioscience's market value can be influenced by many factors that don't directly affect Harvard Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Harvard Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Harvard Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Harvard Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.